144 related articles for article (PubMed ID: 3585139)
1. Anti-Xa activity of human hepatic triglyceride lipase.
Gray E; Bengtsson-Olivecrona G; Olivecrona T; Barrowcliffe TW
J Lab Clin Med; 1987 Jun; 109(6):653-9. PubMed ID: 3585139
[TBL] [Abstract][Full Text] [Related]
2. Anticoagulant activities of pentosan polysulphate (Hémoclar) due to release of hepatic triglyceride lipase (HTGL).
Barrowcliffe TW; Gray E; Merton RE; Dawes J; Jennings CA; Hubbard AR; Thomas DP
Thromb Haemost; 1986 Oct; 56(2):202-6. PubMed ID: 2433786
[TBL] [Abstract][Full Text] [Related]
3. The effects of post-heparin plasma lipases on anti-Xa clotting activity.
Williams SP; Barrowcliffe TW
Thromb Res; 1985 Feb; 37(3):371-7. PubMed ID: 3992526
[TBL] [Abstract][Full Text] [Related]
4. Anti-Xa clotting activities in different hepatic-triglyceride lipase preparations from post-heparin plasma.
Schmidt M; Barrowcliffe TW; Gray E; Watton J; Harenberg J
Thromb Res; 1991 Sep; 63(5):503-8. PubMed ID: 1755003
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins.
Young E; Cosmi B; Weitz J; Hirsh J
Thromb Haemost; 1993 Oct; 70(4):625-30. PubMed ID: 8115988
[TBL] [Abstract][Full Text] [Related]
6. Reactivity of a hereditary abnormal antithrombin III fraction in the inhibition of thrombin and factor Xa.
Tran TH; Bondeli C; Marbet GA; Duckert F
Thromb Haemost; 1980 Oct; 44(2):92-5. PubMed ID: 7455997
[TBL] [Abstract][Full Text] [Related]
7. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
Peyrou V; Béguin S; Boneu B; Hemker HC
Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
[TBL] [Abstract][Full Text] [Related]
8. The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor.
Ofosu FA; Cerskus AL; Hirsh J; Smith LM; Modi GJ; Blajchman MA
Br J Haematol; 1984 Jun; 57(2):229-38. PubMed ID: 6733045
[TBL] [Abstract][Full Text] [Related]
9. A comparison of pentosan polysulphate (SP54) and heparin. I: Mechanism of action on blood coagulation.
Fischer AM; Barrowcliffe TW; Thomas DP
Thromb Haemost; 1982 Apr; 47(2):104-8. PubMed ID: 6179182
[TBL] [Abstract][Full Text] [Related]
10. The effect of Ca2+, phospholipid and factor V on the anti-(factor Xa) activity of heparin and its high-affinity oligosaccharides.
Barrowcliffe TW; Havercroft SJ; Kemball-Cook G; Lindahl U
Biochem J; 1987 Apr; 243(1):31-7. PubMed ID: 3606581
[TBL] [Abstract][Full Text] [Related]
11. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis.
Thomas DP; Merton RE; Barrowcliffe TW; Thunberg L; Lindahl U
Thromb Haemost; 1982 Jun; 47(3):244-8. PubMed ID: 7112499
[TBL] [Abstract][Full Text] [Related]
12. An improved method for removal of antithrombin III from post-heparin plasma lipase fractions with a high recovery rate.
Moriguchi EH; Tamachi H; Homma Y; Goto Y
Tokai J Exp Clin Med; 1991 Mar; 16(1):33-41. PubMed ID: 1780907
[TBL] [Abstract][Full Text] [Related]
13. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin.
Wesselschmidt R; Likert K; Huang Z; MacPhail L; Broze GJ
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):661-9. PubMed ID: 8292716
[TBL] [Abstract][Full Text] [Related]
14. Practical considerations on the measurement of low molecular weight heparin anti-Xa activity.
Aiach M; Roncato M
Semin Thromb Hemost; 1985 Apr; 11(2):108-11. PubMed ID: 4035362
[No Abstract] [Full Text] [Related]
15. [Automatization of heparin determination using chronometric evaluation of anti-Xa activity of the AT III-heparin complex].
Sampol J; Rossi JM; Lejay G
Ann Biol Clin (Paris); 1984; 42(1):21-3. PubMed ID: 6731952
[TBL] [Abstract][Full Text] [Related]
16. Purification and characterization of lipoprotein lipase and hepatic triglyceride lipase from human postheparin plasma: production of monospecific antibody to the individual lipase.
Ikeda Y; Takagi A; Yamamoto A
Biochim Biophys Acta; 1989 Jun; 1003(3):254-69. PubMed ID: 2663075
[TBL] [Abstract][Full Text] [Related]
17. Validity of serine protease inhibition tests in the evaluation and monitoring of the effect of heparin and its fractions.
Hoppensteadt DA; Walenga JM; Fareed J
Semin Thromb Hemost; 1985 Apr; 11(2):112-20. PubMed ID: 3898369
[TBL] [Abstract][Full Text] [Related]
18. Comparison of antithrombotic activity of two heparin fragments PK 10169 (mol. wt. 5,000) and EMT 680 (mol. wt. 2,500) and unfractionated heparin in a rabbit experimental thrombosis model: relative importance of systemic anti-Xa and anti-IIa activities.
Bara L; Trillou M; Mardiguian J; Samama M
Nouv Rev Fr Hematol (1978); 1986; 28(6):355-8. PubMed ID: 3562219
[TBL] [Abstract][Full Text] [Related]
19. Elimination of high affinity heparin fractions and their anticoagulant and lipase activity.
de Swart CA; Nijmeyer B; Andersson LO; Holmer E; Verschoor L; Bouma BN; Sixma JJ
Blood; 1984 Apr; 63(4):836-42. PubMed ID: 6704544
[TBL] [Abstract][Full Text] [Related]
20. Antithrombin III- and heparin cofactor II-mediated anticoagulant and antiprotease actions of heparin and its synthetic analogues.
Jeske W; Fareed J
Semin Thromb Hemost; 1993; 19 Suppl 1():241-7. PubMed ID: 8362268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
